|2.56 0 (0%)||12-08 16:00|
|Targets||6-month :||3.48||1-year :||3.88|
|Resists||First :||2.98||Second :||3.32|
|Supports||First :||2.41||Second :||2|
|MAs||MA(5) :||2.53||MA(20) :||2.74|
|MA(100) :||2.99||MA(250) :||3.05|
|MACD||MACD :||-0.2||Signal :||-0.2|
|%K %D||K(14,3) :||20.9||D(3) :||17|
|52-week||High :||4.84||Low :||2|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RLMD ] has closed above bottom band by 33.1%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||2.57 - 2.59||2.59 - 2.6|
|Low:||2.5 - 2.51||2.51 - 2.53|
|Close:||2.54 - 2.56||2.56 - 2.59|
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||30 (M)|
|Shares Float||23 (M)|
|Held by Insiders||7.8 (%)|
|Held by Institutions||60.6 (%)|
|Shares Short||875 (K)|
|Shares Short P.Month||701 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||3.34|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-48.8 %|
|Return on Equity (ttm)||-83.6 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-77 (M)|
|Levered Free Cash Flow||-39 (M)|
|Price to Book value||0.76|
|Price to Sales||0|
|Price to Cash Flow||-1|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|